Requests that FDA declare that Cyclobenzaprine HCl Sublingual Tablets, 5.6 mg, is suitable for submission as an ANDA
🏛 Food and Drug Administration (FDA)FDA-2026-P-7610
Documents
5
Total comments
0
all analyzed
Comment status
Open
Last activity
—
In this docket
Documents
Rules, notices, and supporting material — the primary rule pinned first.
- Other· Jul 8, 2026No comment period
- Other· Jul 8, 2026No comment period